Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Opdualag | nivolumab and relatlimab-rmbw | Bristol Myers Squibb | N-761234 RX | 2022-03-18 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
opdualag | Biologic Licensing Application | 2024-03-01 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
non-small-cell lung carcinoma | — | D002289 | — |
lymphoma | — | D008223 | C85.9 |
urinary bladder neoplasms | — | D001749 | C67 |
melanoma | — | D008545 | — |
kidney neoplasms | EFO_0003865 | D007680 | C64 |
squamous cell carcinoma | — | D002294 | — |
Expiration | Code | ||
---|---|---|---|
nivolumab / relatlimab, Opdualag, Bristol-Myers Squibb Company | |||
2029-03-18 | Orphan excl. |
Code | Description |
---|---|
J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 2 | 7 | 3 | — | — | 11 |
Colorectal neoplasms | D015179 | — | — | — | 2 | 1 | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | 1 | — | — | 3 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 9 | 11 | — | — | — | 15 |
Carcinoma | D002277 | — | C80.0 | 2 | 8 | — | — | — | 9 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 3 | — | — | — | 4 |
Squamous cell carcinoma | D002294 | — | — | — | 3 | — | — | — | 3 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 3 | — | — | — | 3 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 2 | — | — | — | 3 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 2 | — | — | — | 3 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 2 | — | — | — | 2 |
Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | — | 2 |
Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Drug common name | Relatlimab |
INN | relatlimab |
Description | Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990044 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB14851 |
UNII ID | AF75XOF6W3 (ChemIDplus, GSRS) |